25/100BRoivant Sciences stock forecast 2027–2029What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Roivant Sciences is 47.71, 18.0% above the current price of 40.42. Their targets range from 41.00 to 55.00.
Of the 9 firms that rated Roivant Sciences in the past 12 months, 8 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 41.00 to 55.00, with an average of 47.71.
| Buy | 8 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 55.00 |
| Average target | 47.71 |
| Lowest target | 41.00 |
| Current price | 40.42 |
Roivant Sciences price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Roivant Sciences price target and rating?
How analysts rate Roivant Sciences, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
8 of 9 firms rate it buy now, against 7 of 8 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Roivant Sciences analyst upgrades, downgrades and price targets
The latest rating change came on 12 October 2026, when Wolfe Research downgraded Roivant Sciences from Outperform to Peer Perform. The most recent new target came from Stifel Nicolaus on 16 September 2026: 51.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 12 Oct 2026 | Wolfe Research | Downgraded · Outperform → Peer Perform | — | — | — |
| 16 Sept 2026 | Stifel Nicolaus | — | 51.00 | — | 39.57 |
| 9 Sept 2026 | Guggenheim Yastin Suneja | Reiterated · Buy | 36.00 → 46.00 | +27.8% | 41.48 |
| 9 Sept 2026 | UBS | — | 55.00 | — | 41.48 |
| 8 Sept 2026 | H.C. Wainwright | — | 41.00 → 47.00 | +14.6% | 42.03 |
| 8 Sept 2026 | Jefferies | Reiterated · Buy | 30.00 → 52.00 | +73.3% | 41.70 |
| 7 Aug 2026 | H.C. Wainwright Douglas Tsao | — | 34.00 → 41.00 | +20.6% | 35.12 |
| 26 May 2026 | Guggenheim Yastin Suneja | Reiterated · Buy | 30.00 → 36.00 | +20.0% | 29.96 |
| 21 May 2026 | Cowen & Co. | — | 41.00 | — | 32.18 |
| 21 May 2026 | Leerink Partners David Risinger | — | 32.00 → 42.00 | +31.3% | 32.41 |
| 16 Apr 2026 | Piper Sandler | Reiterated · Overweight | 40.00 | — | 29.26 |
| 4 Mar 2026 | H.C. Wainwright Douglas Tsao | — | 33.00 → 34.00 | +3.0% | 28.81 |
| 10 Feb 2026 | H.C. Wainwright | — | 26.00 → 33.00 | +26.9% | 27.67 |
| 9 Feb 2026 | Jefferies | — | 20.00 → 30.00 | +50.0% | 26.45 |
| 9 Feb 2026 | Guggenheim | Reiterated · Buy | 28.00 → 30.00 | +7.1% | 25.82 |
| 18 Dec 2025 | Guggenheim | — | 25.00 → 28.00 | +12.0% | 22.30 |
| 15 Dec 2025 | Leerink Partners David Risinger | Reiterated · Outperform | 29.00 → 32.00 | +10.3% | 22.10 |
| 12 Dec 2025 | H.C. Wainwright | — | 20.00 → 26.00 | +30.0% | 21.47 |
| 14 Nov 2025 | Guggenheim Yastin Suneja | — | 21.00 → 25.00 | +19.0% | 20.56 |
| 11 Nov 2025 | Leerink Partners David Risinger | — | 29.00 | — | 21.17 |
Roivant Sciences EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does Roivant Sciences beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 27.4% off the result, either way, and their revenue estimate 110.7%, over the last 12 quarters.
- EPS beats
- 11 / 21
- Revenue beats
- 10 / 21
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +21.0%
- Since
- November 2021
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q2 FY2027 | 9 Nov 2026 | -0.37 | -0.27 | +26.4% | 4.34M | 35.12M | +710.0% |
| Q1 FY2027 | 6 Aug 2026 | -0.30 | -0.33 | -10.1% | 2.06M | 1.44M | -29.9% |
| Q4 FY2026 | 20 May 2026 | -0.29 | -0.28 | +3.5% | 3.41M | 2.52M | -26.2% |
| Q3 FY2026 | 6 Feb 2026 | -0.30 | -0.24 | +19.9% | 5.08M | 2.00M | -60.6% |
| Q2 FY2026 | 10 Nov 2025 | -0.32 | -0.20 | +36.9% | 5.62M | 1.57M | -72.0% |
| Q1 FY2026 | 11 Aug 2025 | -0.25 | -0.25 | -0.8% | 7.30M | 2.17M | -70.3% |
| Q4 FY2025 | 29 May 2025 | -0.26 | -0.29 | -10.1% | 54.07M | 7.57M | -86.0% |
| Q3 FY2025 | 10 Feb 2025 | -0.25 | -0.23 | +9.0% | 5.00M | 9.02M | +80.4% |
| Q2 FY2025 | 12 Nov 2024 | -0.25 | -0.29 | -17.4% | 45.92M | 4.48M | -90.3% |
| Q1 FY2025 | 8 Aug 2024 | -0.24 | 0.12 | +149.3% | 30.72M | 55.13M | +79.5% |
| Q4 FY2024 | 30 May 2024 | -0.26 | -0.23 | +13.0% | 31.01M | 28.93M | -6.7% |
| Q3 FY2024 | 13 Feb 2024 | -0.31 | -0.21 | +32.0% | 31.77M | 37.14M | +16.9% |
Roivant Sciences stock price 2027–2029: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
There are no price scenarios for Roivant Sciences: its P/E has been above 60, or from losses, too often in the last five years to price its earnings at, and similar companies' P/Es put its value too far from its price to stand in. The earnings analysts expect are in the estimates above.
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 97.350 | 194.84146Price 97.35244 | +100.1% | |
| 119.980 | 236.63177Price 119.98296 | +97.2% | |
| 197.050 | 384.58163Price 197.052,644 | +95.2% | |
| 157.530 | 305.52161Price 157.53396 | +93.9% | |
| 43.270 | 82.9546Price 43.27165 | +91.7% | |
| 214.470 | 405.52304Price 214.47507 | +89.1% | |
| 163.700 | 308.95212Price 163.70442 | +88.7% |
Furthest below the fair value on each stock's page, updated every day.